Different hormone receptors and their roles as prognostic markers in breast cancer

doi:10.3969/j.issn.1006-7795.2018.04.001

Abstract

Abstract: Breast cancer is one of the leading causes of death in women,and there is an urgent need for new biomarkers and therapeutic targets.The drug treatment response and long-term prognosis of various breast cancer subtypes are different. In cases like triple negative breast cancer estrogen receptor-α(ER-α), progesterone receptor(PR), and human epidermal growth factor receptor-2 (HER-2), there is a complete lack of available biomarkers for prognosis,and therapeutic response is poor. In recent years, in vitro and in vivo experiments have shown that progesterone receptor membrane component 1 (PGRMC1) plays an important role in the occurrence and development of breast cancer. So how do different hormone receptors predict the development and prognosis of breast cancer? Will PGRMC1 be a new potential prognostic marker for breast cancer in the future? We will review the results of related researches.

Key words: breast cancer, progesterone receptor membrane component 1 (PGRMC1), prognostic markers

CLC Number:

R711

Zhang Ying, Ruan Xiangyan, Cai Guiju, Su Yajie, Li Na, Alfred O. Mueck. Different hormone receptors and their roles as prognostic markers in breast cancer[J]. Journal of Capital Medical University, 2018, 39(4): 479-485.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2018.04.001

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2018/V39/I4/479

References

[1] Foulkes W D, Smith I E, Reis-Filho J S. Triple-negative breast cancer[J]. N Engl J Med,2010,363(20):1938-1948.
[2] Dent R, Trudeau M, Pritchard K I, et al. Triple negative breast cancer:clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007,13(15 Pt1):4429-4434.
[3] 张颖, 阮祥燕, 米鑫,等. 孕激素受体膜组分1(PGRMC1)对预测乳腺癌预后作用的研究[J]. 首都医科大学学报,2015,36(4):548-552.
[4] Frasor J, Danes J M, Komm B, et al.Profiling of estrogen up-and down-regulated gene expression in human breast cancer cells:insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype[J]. Endocrinology,2003, 144(10):4562-4574.
[5] Heldring N, Pike A, Andersson S, et al. Estrogen receptors:how do they signal and what are their targets[J]. Physiol Rev,2007,87(3):905-931.
[6] Vrtacnik P, Ostanek B, Mencej-Bedrac S, et al. The many faces of estrogen signaling[J]. Biochem Med (Zagreb),201424(3):329-342.
[7] Jensen E V, Jordan V C. The estrogen receptor:a model for molecular medicine[J]. Clin Cancer Res,2003, 9(6):1980-1989.
[8] Hewitt S C, Korach K S. Estrogen receptors:structure, mechanisms and function[J]. Rev Endocr Metab Disord,2002,3(3):193-200.
[9] Albanito L, Lappano R, Madeo A, et al.G-protein-coupled receptor 30 and estrogen receptor-alpha are involved in the proliferative effects induced by atrazine in ovarian cancer cells[J]. Environ Health Perspect,2008,116(12):1648-1655.
[10] Mehta R G, Hawthorne M, Mehta R R, et al. Differential roles of ER-α and ER-β in normal and neoplastic development in the mouse mammary gland[J]. PLoS One, 2014, 9(11):e113175.
[11] Stope M B, Popp S L, Knabbe C, et al. Estrogen receptor alpha attenuates transforming growth factor-beta signaling in breast cancer cells independent from agonistic and antagonistic ligands[J]. Breast Cancer Res Treat,2010,120(2):357-367.
[12] Taylor A H, Al-Azzawi F. Immunolocalisation of oestrogen receptor beta in human tissues[J]. J Mol Endocrinol,2000, 24(1):145-155.
[13] Carroll J S, Brown M. Estrogen receptor target gene:an evolving concept[J]. Mol Endocrinol, 2006,20(8):1707-1714.
[14] Kastner P, Krust A, Turcotte B, et al. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B[J]. EMBO J,1990,9(5):1603-1614.
[15] Soyal S, Ismail P M, Li J, et al. Progesterone's role in mammary gland development and tumorigenesis as disclosed by experimental mouse genetics[J]. Breast Cancer Res,2002, 4(5):191-196.
[16] Conneely O M, Mulac-Jericevic B, Lydon J P. Progesterone-dependent regulation of female reproductive activity by two distinct progesterone receptor isoforms[J].Steroids,2003, 68(10-13):771-778.
[17] Mulac-Jericevic B, Lydon J P, DeMayo F J,et al. Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform[J]. Proc Natl Acad Sci U S A,2003,100(7):9744-9749.
[18] Richer J K, Jacobsen B M, Manning N G, et al. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells[J]. J Biol Chem,2002,277(7):5209-5218.
[19] Hopp T A, Weiss H L, Hilsenbeck S G, et al. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates[J]. Clin Cancer Res, 2004, 10(8):2751-2760.
[20] Cahill M A. Progesterone receptor membrane component 1:an integrative review[J]. J Steroid Biochem Mol Biol, 2007,105:16-36.
[21] Jeng M H, Parker C J, Jordan V C.Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation[J].Cancer Res,1992,52(23):6539-6546.
[22] Neubauer H, Ruan X, Schneck H.Overexpression of progesterone receptor membrane component 1:possible mechanism for increased breast cancer risk with norethisterone in hormone therapy[J].Menopause,2013,20(5):504-510.
[23] Ruan X,Neubauer H,Yang Y. Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells[J].Climacteric,2012,15(5):467-472.
[24] AIRTUM Working Group, CCM, AIEOP Working Group. Italian cancer figures, report 2012:cancer in children and adolescents[J]. Epidemiol Prev,2013,37(1 Suppl 1):1-225.
[25] McDonnell D P, Chang C Y, Nelson E R. The estrogen receptor as a mediator of the pathological actions of cholesterol in breast cancer[J].Climacteric, 2014,17 Suppl 2:60-65.
[26] Kuiper G G, Carlsson B, Grandien K,et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta[J]. Endocrinology, 1997, 138(3):863-870.
[27] Guo L, Meng J, Yilamu D, et al. Significance of ER-β expression in different molecular subtypes of breast cancer[J]. Diagn Pathol,2014,9:20.
[28] Ignatiadis M, Sotiriou C. Luminal breast cancer:from biology to treatment[J]. Nat Rev Clin Oncol,2013,10(9):494-506.
[29] Skliris G P, Leygue E, Curtis-Snell L, et al. Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours[J]. Br J Cancer,2006,95(5):616-626.
[30] Yan Y, Li X, Blanchard A, et al. Expression of both estrogen receptor-beta 1(ER-β1) and its co-regulator steroid receptor RNA activator protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with estrogen receptor-alpha (ER-α)-negative early breast cancer (EBC)[J]. Ann Oncol,2013,24(8):1986-1993.
[31] Liu J, Guo H, Mao K,et al. Impact of estrogen receptor-β expression on breast cancer prognosis:a meta-analysis[J]. Breast Cancer Res Treat,2016,156(1):149-162.
[32] Wu X, Subramaniam M, Grygo S B,et al. Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen[J]. Breast Cancer Res,2011,13(2):R27.
[33] Elebro K, Borgquist S, Simonsson M,et al. Combined androgen and estrogen receptor status in breast cancer:treatment prediction and prognosis in a population-based prospective cohort[J]. Clin Cancer Res,2015,21(16):3640-3650.
[34] Cui X, Schiff R, Arpino G, et al. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy[J]. J Clin Oncol,2005,23(30):7721-7735.
[35] Bardou V J, Arpino G, Elledge R M, et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases[J]. J Clin Oncol,2003,21(10):1973-1979.
[36] Bae S Y, Kim S, Lee J H, et al. Poor prognosis of single hormone receptor-positive breast cancer:similar outcome as triple-negative breast cancer[J]. BMC Cancer,2015,15:138.
[37] Yang L H, Tseng H S, Lin C, et al. Survival benefit of tamoxifen in estrogen receptor-negative and progesterone receptor-positive low grade breast cancer patients[J]. J Breast Cancer,2012, 15(3):288-295.
[38] Richer J K, Jacobsen B M, Manning N G, et al. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells[J]. J Biol Chem,2002, 277(7):5209-5218.
[39] Bamberger A M, Milde-Langosch K, Schulte H M, et al. Progesterone receptor isoforms, PR-B and PR-A, in breast cancer:correlations with clinicopathologic tumor parameters and expression of AP-1 factors[J]. Horm Res, 2000, 54(1):32-37.
[40] 杜娟,阮祥燕.三阴乳腺癌的特点及研究进展[J].首都医科大学学报,2015,36(4):578-582.
[41] 郑红梅,李祥,金立亭,等.三阴性乳腺癌基因学分子分型和个体化治疗新进展[J].中华肿瘤防治杂志, 2016,23(17):1198-1204.
[42] Aydiner A, Sen F, Tambas M,et al. Metaplastic breast carcinoma versus triple-negative breast cancer:survival and response to treatment[J].Medicine (Baltimore),2015,94(52):e2341.
[43] Neubauer H,Yang Y, Seeger H, et al. The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells[J].Menopause,2011,18(8):845-850.
[44] Neubauer H, Chen R, Schneck H, et al.Membrane-initiated effects of progestogens on proliferation and downstream signal cascades in MCF-7 breast cancer cells[J].Horm Mol Biol Clin Investig,2011,6(1):185-192.
[45] Zhang Y, Ruan X, Willibale M, et al. May progesterone receptor memebrane component 1(PGRMC1) predict the risk of breast cancer?[J].Gynecol Endocrinol, 2016,32(1):58-60.
[46] 王利娟,阮祥燕,赵越.PGRMC1在乳腺癌组织中的表达及其与临床病理特征的相关性[J].首都医科大学学报,2018,39(2):272-276.
[47] Thomas P, Pang Y, Dong J. Enhancement of cell surface expression and receptor functions of membrane progestin receptor α (mPRα) by progesterone receptor membrane component 1(PGRMC1):evidence for a role of PGRMC1 as an adaptor protein for steroid receptors[J]. Endocrinology, 2014,155(3):1107-1119.
[48] Peluso J J,Pappalardo A,Losel R,et al.Expression and function of PAIRBP1 within gonadotropin-primed immature rat ovaries:PAIRBP1 regulation of granulosa and luteal cell viability[J].Biol Reprod,2005,73(2):261-270.
[49] Crudden G, Chitti R E, Craven R J.Hpr6(heme-1 domain protein) regulates the susceptibility of cancer cells to chemotherapeutic drugs[J].J Pharmacol Exp Ther, 2006,316(1):448-455.
[50] Ruan X, Zhang Y, Mueck A O, et al. Increased expression of progesterone receptor memebrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and negative breast cancer[J].Menopause,2017,24(2):203-209.
[51] Clark N C, Friel A M, Pru C A, et al. Progesterone receptor membrane component 1 promotes survival of human breast cancer cells and the growth of xenograft tumors[J]. Cancer Biol Ther, 2016,17(3):262-271.
[52] Gnant M, Thomssen C, Harbeck N. St. Gallen/Vienna 2015:a brief Summary of the consensus discussion[J]. 2015,10(2):124-130.
[53] Otsuka I, Takahashi S, O'uchi K, et al.Clinicopathological features of endometrial carcinoma in tamoxifen-and toremifene-treated breast cancer patients[J].Gan To Kagaku Ryoho,2010,37(2):279-283.
[54] Leung F, Terzibachian J J, Govyadovskiy A, et al.Tamoxifen in the adjuvant setting for breast cancer:reflexions about the risk of uterine carcinosarcoma[J]. Gynecol Obstet Fertil,2009,37(5):447-451.
[55] Heikinheimo O, Gemzell-Danielsson K. Emerging indications for the levonorgestrel-releasing intrauterine system (LNG-IUS)[J]. Acta Obstet Gynecol Scand,2012,91(1):3-9.
[56] Depypere H, Inki P. The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy:a clinical review[J]. Climacteric, 2015,18(4):470-482.
[57] Dominick S, Hickey M, Chin J,et al. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen[J]. Cochrane Database Syst Rev,2015,(12):CD007245.
[58] Trinh X B, Tjalma W A, Makar A P, et al. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients[J]. Fertil Steril,2008,90(1):17-22.
[59] Fu Y, Zhuang Z.Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients:a meta-analysis[J].Int J Clin Exp Pathol,2014,7(10):6419-6429.